“There’s nothing beyond good and bad cholesterol.” For years, this is the answer many people received when they asked how to truly assess their heart health. Yet it isn’t true. The classic lipid panel — total cholesterol, LDL, HDL and triglycerides — is a good starting point, but it doesn’t tell the whole story. Two people with the same LDL cholesterol value can have a very different cardiovascular risk. Advanced lipidomics now makes it possible to see what cholesterol alone conceals. In this article we explain what it measures, why it matters and — above all — how to interpret it honestly.
Why LDL and HDL aren’t enough
The classic panel measures how much cholesterol is carried in the blood, not how many particles carry it. This is far from a theoretical difference: for the same LDL cholesterol level, the number of particles can vary considerably. And it is the particles, not cholesterol itself, that penetrate the artery wall and trigger the process that leads to plaque.
This phenomenon is called discordance: LDL cholesterol may appear “within range” while the real particle burden is high. Relying on LDL alone, in these cases, risks underestimating the danger.
It’s the particles that count, not just cholesterol: apoB and Lp(a)
Apolipoprotein B (apoB) is present in every atherogenic particle: measuring it means counting how many of these particles are actually circulating. For this reason it is considered an indicator of the “real atherogenic burden” and is recommended by the European guidelines (ESC/EAS), particularly when triglycerides are high or in the presence of metabolic conditions.
Alongside apoB, lipoprotein(a) or Lp(a) is a largely inherited risk factor: it only needs to be measured once in a lifetime. If elevated, it increases cardiovascular risk independently of other values, and it is valuable information precisely because it is so often overlooked.
Not all LDL is the same: the subclasses
LDL particles are not all identical. There is a profile with large, “fluffy” particles (phenotype A) and one with small, dense particles (phenotype B). Small, dense LDL penetrate the artery wall more easily, remain there longer and oxidize more readily: they are, in other words, the most insidious.
Subclass analysis reveals which profile a patient has — a detail that is particularly useful in those with elevated triglycerides, metabolic syndrome or insulin resistance, where the “small and dense” phenotype is more common.
The Ceramide Risk Score: risk beyond cholesterol
Ceramides are bioactive lipids involved in inflammation and plaque instability. The Ceramide Risk Score — validated in studies involving tens of thousands of people — estimates the risk of cardiovascular events in the short to medium term, and it does so independently of LDL cholesterol.
It is important to be clear about what it is and what it is not: it is a prognostic marker, that is, a tool that adds information about risk beyond what traditional lipids provide. It does not replace the other tests, but complements them, contributing to a finer risk stratification. It is a specialist test, which at Sorengo we offer as part of an integrated assessment.
More information and more transparency: this is how trust is built
The value of all this lies not only in offering more tests, but in interpreting them honestly: explaining to the patient what each result can — and cannot — tell them. Going beyond cholesterol does not mean promising certainties, but applying what scientific evidence already allows, communicating it rigorously.
It is not a contradiction of traditional medicine: it is doing well what the guidelines already suggest — apoB and Lp(a) are an example — adding a validated level of depth. It is a concrete way of recognizing the patient as a person, and of guiding them toward prevention choices based on the real picture, not on a single number.
Conclusion
The classic lipid panel is the starting point, not the finish line. apoB, Lp(a), LDL subclass analysis and the Ceramide Risk Score allow us to build a more complete and personalized picture of cardiovascular risk. At Medical Center Sorengo we combine advanced diagnostics with a simple principle: explaining every result to you with clarity and transparency.
Book an advanced cardiovascular prevention consultation.
📍 Via Ponte Tresa 35, 6924 Sorengo (Lugano) · 📞 091 994 20 00 · ✉️ info@mcsorengo.ch · 🌐 mcsorengo.ch
The Science of Healing. The Art of Caring.